Efficacy and Safety of Transurethral Columnar Balloon Dilation of the Prostate for the Treatment of Benign Prostatic Hyperplasia: A Multicenter Trial
Table 1
Patient general information.
Features
Mean ± SD
Median
Range
Age (year)
73.04 ± 10.78
74
10-42
Prostate volume (mL)
51.23 ± 31.70
43
8-381
Body mass index
27.50 ± 2.21
27.54
18.33-31.02
Serum PSA levels (ng/mL)
6.74 ± 3.97
6.7
0.46-42.26
IPSS scores
21.47 ± 3.46
22
16-32
QoL
4.54 ± 1.09
5
3-6
Qmax (mL/s)
8.91 ± 3.13
8.81
3.56-14.36
PVR (mL)
180.69 ± 44.33
179.27
105.12-255.88
IIEF-5
20.96 ± 2.03
21
13-25
MSHQ-EjD-SF
10.47 ± 1.72
10
8-13
Note: QoL: quality of life; Qmax: maximum urinary flow rate; PVR: Postvoid Residual Urine Volume; IIEF-5: International Index of Erectile Function; MSHQ-EjD-SF: Male Sexual Health Questionnaire-Ejaculatory Dysfunction Short Form.
